Trajectory of left ventricular ejection fraction among individuals eligible for implantable cardioverter-defibrillator

Selma Carlson, Amy Gravely, Selçuk Adabag

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


OBJECTIVE: Examine the trajectory of left ventricular ejection fraction (EF) among patients eligible for implantable cardioverter-defibrillator (ICD) therapy.

BACKGROUND: EF is the cornerstone criterion for ICD therapy, but the risk of sudden cardiac death remains after an improvement in EF.

METHODS: We examined the trajectory of EF among 1178 participants of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) who had three or more assessments of EF, at least 90 days apart. A follow-up EF > 35% or >10% absolute increase in EF from baseline were examined as the criteria for EF improvement.

RESULTS: At first follow-up, 381 (32%) patients had an improvement of EF to >35%. However, EF had returned back to ≤35% in 109 (27%) of these patients at second follow-up. Similarly, 446 (38%) patients experienced a >10% improvement in EF at first follow-up, but 109 (24%) of these had a subsequent >10% decrease in EF at the second follow-up. Of the 32 patients with normalized EF (≥55%) at first follow-up, 18 (56%) had a subsequent >10% decrease in EF. The fluctuation in EF was present in both ischemic and nonischemic cardiomyopathy but a higher proportion of patients with nonischemic cardiomyopathy had an improvement in EF to >35% at first follow-up compared to those with ischemic cardiomyopathy (38% vs. 27%, p = < .0001).

CONCLUSION: There is substantial fluctuation of EF among patients who are eligible for ICD therapy.

Original languageEnglish (US)
Pages (from-to)800-806
Number of pages7
JournalPACE - Pacing and Clinical Electrophysiology
Issue number5
StatePublished - May 2021

Bibliographical note

Funding Information:
We are grateful to the SCD-HeFT trial investigators and to NHLBI BioLINCC for the opportunity to access these data. This manuscript is the result of work supported with resources and use of facilities of the Minneapolis VA Health Care System. The contents do not represent the views of the United States Department of Veterans Affairs or the US government.

Funding Information:
Dr. Selçuk Adabag has received research grants from Medtronic.

Publisher Copyright:
© 2021 Wiley Periodicals LLC


  • EF
  • ICD
  • LVEF
  • cardiomyopathy
  • ejection fraction
  • heart failure
  • implantable cardioverter-defibrillator
  • trajectory

PubMed: MeSH publication types

  • Journal Article
  • Randomized Controlled Trial


Dive into the research topics of 'Trajectory of left ventricular ejection fraction among individuals eligible for implantable cardioverter-defibrillator'. Together they form a unique fingerprint.

Cite this